304015-61-0

Upstream product

• 18226-17-0 N,N-bis(2-hydroxyethyl)-4-nitroaniline 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 528836-41-1 diallyl 4-{[4'-bis(2''-tert-butyldimethylsilyloxyethyl)aminophenyl]-N-methylcarbamoyloxymethyl}phenylcarbamoyl-L-glutamate 
• 528836-39-7 diallyl 4-{[4'-bis(2''-tert-butyldimethylsilyloxyethyl)aminophenyl]carbamoyloxymethyl}phenylcarbamoyl-L-glutamate 
• 528836-42-2 di-tert-butyl 4-{[4'-bis(2''-(tert-butyldimethylsilyloxy)ethyl)aminophenyl]-N-methylcarbamoyloxymethyl}phenyloxycarbonyl L-glutamate 
• 528836-40-0 di-tert-butyl 4-{[4'-bis(2''-(tert-butyldimethylsilyloxy)ethyl)aminophenyl]carbamoyloxymethyl}phenyloxycarbonyl L-glutamate 
• 528836-50-2 diallyl 4-{N-[4'-bis(2''-mesyloxyethyl)aminophenyl]-N-methylcarbamoyloxymethyl}phenylcarbamoyl-L-glutamate 
• 528836-48-8 diallyl 4-{[4'-(N,N-bis(2''-mesyloxyethyl)amino)phenyl]carbamoyloxymethyl}phenylcarbamoyl-L-glutamate 
• 528836-49-9 di-tert-butyl 4-{[4'-(N,N-bis(2''-mesyloxyethyl)amino)phenyl]carbamoyloxymethyl}phenyloxycarbonyl-L-glutamate 
• 528836-56-8 diallyl 4-{N-[4'-bis(2''-iodoethyl)aminophenyl]-N-methylcarbamoyloxymethyl}phenylcarbamoyl-L-glutamate 
• 528836-54-6 diallyl 4-{[4'-(N,N-bis(2''-iodoethyl)amino)phenyl]carbamoyloxymethyl}phenylcarbamoyl-L-glutamate 
• 528836-45-5 diallyl 4-{N-[4'-bis(2''-hydroxyethyl)aminophenyl]-N-methylcarbamoyloxymethyl}phenylcarbamoyl-L-glutamate 
• 528836-62-6 diallyl 4-{N-[4'-bis(2''-bromoethyl)aminophenyl]-N-methylcarbamoyloxymethyl}phenylcarbamoyl-L-glutamate 
• 528836-55-7 di-tert-butyl 4-{[4'-(N,N-bis(2''-iodoethyl)amino)phenyl]carbamoyloxymethyl}phenyloxycarbonyl-L-glutamate 
• 528836-43-3 diallyl 4-{[4'-(N,N-bis(2''-hydroxyethyl)amino)phenyl]carbamoyloxymethyl}phenylcarbamoyl-L-glutamate 
• 528836-61-5 diallyl 4-{[4'-(N,N-bis(2''-bromoethyl)amino)phenyl]carbamoyloxymethyl}phenylcarbamoyl-L-glutamate 

Relevant academic research and scientific papers

TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS

The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.

ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS

This invention pertains to certain enzyme (CPG2) activated self-immolative nitrogen mustard prodrugs, which are useful in enzyme prodrug therapy (EPT), such as ADEPT and GDEPT, for the treatment of proliferative conditions, such as cancer, and which have

Synthesis and Evaluation of Nitroheterocyclic Carbamate Prodrugs for Use with Nitroreductase-Mediated Gene-Directed Enzyme Prodrug Therapy

A variety of nitroheterocyclic carbamate prodrugs of phenylenediamine mustard and 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1, 2-dihydro-3H-benz[e]indoline (aminoseco-CBI-TMI), covering a wide range of reduction potential, were pre

Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT

Nineteen novel potential self-immolative prodrugs and their corresponding drugs have been synthesized for gene-directed enzyme prodrug therapy (GDEPT) with carboxypeptidase G2 (CPG2) as the activating enzyme. The compounds are derived from o- and p-amino